Hangzhou Bangshun Pharmaceutical Co., Ltd.

杭州邦顺制药股份有限公司

Develops and commercializes oral small-molecule drugs for oncology and autoimmune diseases, with a pipeline including NMPA-approved bezacitinib, a JAK inhibitor for myelofibrosis, and one registrational candidate, operating in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Social insurance & housing fund
• Intellectual property
• Customer concentration
• Supplier concentration
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Net current liabilities or net liabilities
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech